Advance amount related to milestone payment.

No definition available.

Name:	LIXT_AdvanceAmountRelatedToMilestonePayment
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount related to milestone payment.

+ References

No definition available.

+ Details

Name:	LIXT_AmountRelatedToMilestonePayment
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Company is obligated to pay annual license maintenance fee.

+ References

No definition available.

+ Details

Name:	LIXT_AnnualLicenseMaintenanceFee
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Consulting and advisory quarterly cash fee.

+ References

No definition available.

+ Details

Name:	LIXT_ConsultingAndAdvisoryCashFee
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contract price.

+ References

No definition available.

+ Details

Name:	LIXT_ContractPrice
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Estimated work cost.

+ References

No definition available.

+ Details

Name:	LIXT_EstimatedWorkCost
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of expected paymen through software.

+ References

No definition available.

+ Details

Name:	LIXT_ExpectedPaymentThroughSoftware
Namespace Prefix:	LIXT_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Expected payment in services.

+ References

No definition available.

+ Details

Name:	LIXT_ExpectedPaymentinServices
Namespace Prefix:	LIXT_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Company is obligated to pay non refundable license issue fee..

+ References

No definition available.

+ Details

Name:	LIXT_NonRefundableLicenseIssueFee
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones.

+ References

No definition available.

+ Details

Name:	LIXT_PaymentsOnNonrefundableMilestone
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Reimbursement expense.

+ References

No definition available.

+ Details

Name:	LIXT_ReimbursementExpense
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

+ Details

Name:	us-gaap_ContractualObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

+ Details

Name:	us-gaap_DeferredCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of expense for employee benefit and equity-based compensation.

+ References

No definition available.

+ Details

Name:	us-gaap_EmployeeBenefitsAndShareBasedCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482425/460-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-4

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-4

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-9

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_OfficersCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingCostsAndExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Cash payments to lessor's for use of assets under operating leases.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForRent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.

+ References

+ Details

Name:	us-gaap_SalariesAndWages
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.

+ References

No definition available.

+ Details

Name:	us-gaap_SalariesWagesAndOfficersCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_TitleOfIndividualAxis=LIXT_FormanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=srt_OfficerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_OtherClinicalAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=LIXT_ExecutiveOfficersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=LIXT_Dr.JamesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=LIXT_BastiaanVanDerBaanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details Narrative)												2 Months Ended	3 Months Ended		8 Months Ended	9 Months Ended
Commitments and Contingencies (Details Narrative)	Oct. 05, 2023 USD ($)	Sep. 26, 2023 USD ($)	Jun. 22, 2023 USD ($)	Apr. 17, 2023 USD ($)	Nov. 06, 2022 USD ($)	Jun. 10, 2022 USD ($)	Apr. 09, 2021 USD ($)	Feb. 05, 2021 USD ($)	Aug. 20, 2018 USD ($)	Sep. 14, 2015 USD ($)	Dec. 24, 2013 USD ($)	Aug. 31, 2020 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Oct. 03, 2023 USD ($)	Oct. 03, 2023 EUR (€)	Oct. 08, 2021 EUR (€)
Loss Contingencies [Line Items]
Contractual commitment													$ 6,262,000		$ 6,262,000	$ 6,262,000
Research and development costs													132,487	$ 272,388		749,029	$ 895,649
Aggregate commitments expected													84,000		84,000	84,000
Forman [Member]
Loss Contingencies [Line Items]
Compensation					$ 200,000
Paid office rent					$ 1,500								7,323			11,436
Officer [Member]
Loss Contingencies [Line Items]
Compensation		$ 950,000
Officer [Member] \| Minimum [Member] \| Subsequent Event [Member]
Loss Contingencies [Line Items]
Compensation	$ 700,000
City of Hope [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected													74,181		74,181	74,181
Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Loss Contingencies [Line Items]
Research and development costs																148,138
GEIS [Member]
Loss Contingencies [Line Items]
Amount related to milestone payment																	684,652
NDA Consulting Corp [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee											$ 4,000		4,000	4,000		12,000	12,000
Clinical Trial Research Agreement [Member]
Loss Contingencies [Line Items]
Research and development process costs													0	9,218		0	18,623
Research and development costs															131,074
Other Clinical Agreements [Member]
Loss Contingencies [Line Items]
Research and development costs																1,144,000
Collaboration Agreement [Member] \| GEIS [Member]
Loss Contingencies [Line Items]
Research and development costs																268,829	0
Aggregate commitments expected													3,423,000		3,423,000	3,423,000
Collaboration Agreement [Member] \| Bio Pharma Works LLC [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee										$ 10,000
Reimbursed expense													30,000	30,000		90,000	90,000
Clinical Research Support Agreement [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected													800,000		800,000	800,000
Clinical Research Support Agreement [Member] \| City of Hope [Member]
Loss Contingencies [Line Items]
Research and development costs																69,001	0
Aggregate commitments expected													2,433,000		2,433,000	2,433,000
Total costs													447,512		447,512	447,512
Work Order Agreement [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected													144,000		144,000	144,000
Total costs													10,000		10,000	10,000
Work Order Agreement [Member] \| City of Hope [Member]
Loss Contingencies [Line Items]
Research and development costs								$ 335,000
Aggregate commitments expected													262,000		262,000	262,000
Advance amount related to milestone payment													4,500	7,731		15,740	23,466
Work Order Agreement [Member] \| Theradex Systems, Inc. [Member]
Loss Contingencies [Line Items]
Research and development costs													3,750			10,000
Work cost			$ 153,000
Percentage of payment through services			72.00%
Percentage of payment through software			28.00%
Work Order Agreement [Member] \| Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Loss Contingencies [Line Items]
Research and development costs													566	11,953		20,850	19,792
Exclusive License Agreement [Member] \| Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Loss Contingencies [Line Items]
Non refundable license issue fee									$ 25,000
Maintenance fee									25,000
Payment on non refundable milestone									$ 1,897,000
Operating costs and expenses													21,507	6,301		9,109	18,699
Employment Agreement [Member] \| Executive Officers [Member]
Loss Contingencies [Line Items]
Salary and compensation												$ 640,000
Employment Agreement [Member] \| Dr.James [Member]
Loss Contingencies [Line Items]
Annual compensation							$ 775,000
Employment Agreement [Member] \| Bastiaan van der Baan [Member]
Loss Contingencies [Line Items]
Annual salary		$ 150,000
Development Collaboration Agreement [Member] \| Netherlands Cancer Institute [Member]
Loss Contingencies [Line Items]
Research and development costs																416,356
Aggregate commitments expected													316,000		$ 316,000	316,000				€ 391,000
Advance amount related to milestone payment													51,568	46,068		156,949	149,184
Development Collaboration Agreement [Member] \| Netherlands Cancer Institute [Member] \| Subsequent Event [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected																		$ 263,000	€ 250,000
MRI Global [Member]
Loss Contingencies [Line Items]
Research and development costs																241,841
Advance amount related to milestone payment													$ 19,845	$ 5,549		$ 27,028	$ 25,902
Contract price				$ 326,274		$ 273,980